Royce & Associates LP Raises Stock Holdings in Enfusion, Inc. (NYSE:ENFN)

Royce & Associates LP lifted its position in shares of Enfusion, Inc. (NYSE:ENFN - Free Report) by 84.6% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 184,078 shares of the company's stock after acquiring an additional 84,363 shares during the quarter. Royce & Associates LP owned approximately 0.14% of Enfusion worth $1,896,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Paloma Partners Management Co purchased a new position in shares of Enfusion in the third quarter valued at $157,000. Centiva Capital LP boosted its stake in Enfusion by 5.0% in the 3rd quarter. Centiva Capital LP now owns 25,596 shares of the company's stock worth $243,000 after purchasing an additional 1,227 shares during the period. Azora Capital LP grew its holdings in Enfusion by 6.8% during the 3rd quarter. Azora Capital LP now owns 29,827 shares of the company's stock valued at $283,000 after buying an additional 1,890 shares in the last quarter. Quest Partners LLC bought a new stake in shares of Enfusion during the third quarter valued at about $308,000. Finally, Rhumbline Advisers lifted its holdings in shares of Enfusion by 3.0% in the fourth quarter. Rhumbline Advisers now owns 62,464 shares of the company's stock worth $643,000 after buying an additional 1,796 shares in the last quarter. Hedge funds and other institutional investors own 81.05% of the company's stock.

Insider Buying and Selling

In other news, CEO Oleg Movchan sold 11,452 shares of the stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $11.39, for a total transaction of $130,438.28. Following the completion of the sale, the chief executive officer now directly owns 631,847 shares in the company, valued at approximately $7,196,737.33. This represents a 1.78 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Bradley Herring sold 4,134 shares of the firm's stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $10.13, for a total value of $41,877.42. Following the completion of the sale, the chief financial officer now directly owns 266,369 shares in the company, valued at $2,698,317.97. The trade was a 1.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 77,346 shares of company stock worth $868,109 in the last ninety days. 36.44% of the stock is owned by insiders.

Remove Ads

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Stifel Nicolaus upped their target price on shares of Enfusion from $11.00 to $13.00 and gave the stock a "buy" rating in a report on Wednesday, December 18th. Piper Sandler boosted their price target on shares of Enfusion from $10.00 to $11.50 and gave the company a "neutral" rating in a research report on Monday, December 23rd. Finally, William Blair reiterated a "market perform" rating on shares of Enfusion in a research report on Monday, January 13th.

Enfusion Stock Performance

ENFN traded down $0.01 during trading on Tuesday, reaching $11.13. The stock had a trading volume of 869,226 shares, compared to its average volume of 537,093. The business has a 50-day moving average of $11.16 and a 200-day moving average of $10.13. Enfusion, Inc. has a one year low of $7.83 and a one year high of $11.80. The stock has a market cap of $1.44 billion, a PE ratio of 278.32, a PEG ratio of 1.85 and a beta of 0.95.

Enfusion (NYSE:ENFN - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The company reported $0.01 earnings per share for the quarter, missing analysts' consensus estimates of $0.03 by ($0.02). The firm had revenue of $52.94 million for the quarter, compared to analysts' expectations of $53.98 million. Enfusion had a net margin of 1.70% and a return on equity of 6.67%. Equities research analysts forecast that Enfusion, Inc. will post 0.06 EPS for the current fiscal year.

Enfusion Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.